GlaxoSmithKline Pharmaceuticals has informed that in reference to the communications dated August 1, 2025 received from National Stock Exchange of India, bearing reference number: NSE/CM/Surveillance/15703, and from BSE Limited, bearing reference number: L/SURV/ONL/RV/AJ/ (2025-2026)/ 54, seeking clarification regarding the news article published on https://www.moneycontrol.com on August 1, 2025, titled 'Trump Tariff News Live: GSK and AstraZeneca among top companies told to 'cut US prices or else'. At the outset, it is clarified that the said news item does not pertain to GlaxoSmithKline Pharmaceuticals (the Company). Instead, it concerns GSK plc (previously GlaxoSmithKline plc), our ultimate parent company in the United Kingdom. The Company does not have any further information regarding the events stated in the said article and is therefore unable to comment on any material impact of the same on the Company. The Company is also not aware of any information or announcement, including any pending announcement, which in the Company’s opinion, could have a bearing on the share price of the Company. Accordingly, at present, the Company does not have any information concerning the events stated in the said article which is disclosable in terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The above information is a part of company’s filings submitted to BSE.
